Evidence map›Paper›PMID 27788731›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2016

[Research advances in withdrawal of nucleos(t)ide analogues in chronic hepatitis B patients].

N Hu, H You

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. [Progress of therapeutic vaccinations for chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Article
  2. [Off-treatment responses and predictors and after long-term anti-HBV therapy with nucleos(t)ide analogues].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

N HuDepartment of Internal Medicine, Shandong Medical College, Linyi Shandong Province 276000, China.
H YouLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Withdrawal of nucleos(t)ide analogues in chronic hepatitis B patients has always been a clinical problem for scholars and patients. Many studies showed that the withdrawal of nucleos(t)ide analogues often leads to a high recurrence rate in clinical practice. The factors such as age, baseline HBV DNA load, time of drug consolidation therapy, and HBsAg level are associated with recurrence after withdrawal of nucleos(t)ide analogues. In addition, there are many studies on safety after withdrawal of nucleos(t)ide analogues and response to retreatment after recurrence. This article reviews the research advances in the aspects mentioned above.

Indexed as

AdultAntiviral AgentsFemaleHepatitis B, ChronicHepatitis B Surface AntigensHepatitis B virusHumansMaleNucleosidesNucleotidesRecurrenceTreatment OutcomeAntiviral AgentsHepatitis B Surface AntigensNucleosidesNucleotides

Identifiers

PMID27788731
PMCPMC12769119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.